Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | UBE2N | P61088 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PDE1A | P54750 | 1/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.54 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 7/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15869886 | 0.94 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAHTTUBE2NMAPK1 | |
| SCHEMBL14907924 | 0.91 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTUBE2NMAPK1 | |
| SCHEMBL15869887 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAHTTUBE2NMAPK1 | |
| SCHEMBL556216 | 0.81 | SMN1; SMN2 (0.80) | SMN1; SMN2LMNAHTTUBE2NMAPK1 | |
| SCHEMBL14907925 | 0.81 | MAPK1 (0.55) | MAPK1ADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL15870738 | 0.78 | ADORA2A (0.54) | SMN1; SMN2LMNAHTTUBE2NMAPK1 | |
| SCHEMBL19006847 | 0.77 | PDE1A (0.60) | SMN1; SMN2LMNAHTTUBE2NMAPK1 | |
| SCHEMBL17750785 | 0.76 | LMNA (0.89) | SMN1; SMN2LMNAHTTUBE2NMAPK1 | |
| SCHEMBL555839 | 0.76 | PDE1A (0.67) | SMN1; SMN2LMNAHTTUBE2NMAPK1 | |
| SCHEMBL21360607 | 0.76 | TRPA1 (0.47) | LMNAMAPK1GLATP53PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2013062762-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | SNCA, PARK7, APP | SMN1; SMN2 20/4885LMNA 1005/4885HTT 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.